Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2345-2351

  Kuriyama, Shigeki ^a   Tominaga, Kentaro ^a   Kikukawa, Masaji ^a   Nakatani, Toshiya ^a   Tsujinoue, Hirohisa ^a   Yamazaki, Masaharu ^a   Nagao, Shintaro ^a   Toyokawa, Yasunori ^a   Mitoro, Akira ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus; Anti adenovirus antibody; Gene therapy; Gene transfer; Human serum; Neutralizing antibody

Indexed keywords

VIRUS ANTIBODY;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GENE TRANSFER; IMMUNOGENICITY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SERUM;

3T3 CELLS; ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; BETA-GALACTOSIDASE; BLOOD; CELL LINE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; KIDNEY; LIVER; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 15144349956     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Yei S, Mittereder N, Tang K, O'Sullivan C and Trapnell BC: Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1: 192-200, 1994.
2. Goldman MJ, Litzky LA, Engelhardt JF and Wilson JM: Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther 6: 839-851, 1995.
3. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SLC and Eisensmith RC: Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3: 217-222, 1996.
4. Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I and Wilson JM: Prolonged metabolic correction in adult ornithine transcarbamylae-deficient mice with adenoviral vectors. J Biol Chem 271: 3639-3646, 1996.
5. Quantin B, Perricaudet LD, Tajbakhsh S and Mandel J-L: Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 89: 2581-2584, 1992.
6. Tripathy SK, Black HB, Goldwasser E and Leiden JM: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 2: 545-550, 1996.
7. Setoguchi Y, Jaffe HA, Danel C and Crystal RG: Ex vivo and in vivo gene transfer to the skin using replication-deficient adenovirus vectors. J Invest Dermatol 102: 415-421, 1994.
8. Moullier P, Friedlander G, Calise D, Ronco P, Perricaudet M and Ferry N: Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int 45: 1220-1225, 1994.
9. Byrnes AP, Wood MJA and Charlton HM: Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther 3: 644-651, 1996.
10. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT and Danel C: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8: 42-51, 1994.
11. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, Accart N, Layani MP, Aymard M, Bernon H, Bienvenu J, Courtney M, Doring G, Gilly B, Gilly R, Lamy D, Levrey H, Morel, Y, Paulin C, Perraud F, Rodillon L, Sene C, So S, Touraine-Moulin F, Schatz C and Pavirani A: Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 8: 15-25, 1997.
12. Yang Y, Li Q, Ertl HCJ and Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004-2015, 1995.
13. Kaplan JM, St George JA, Pennington SE, Keyes LD, Johnson RP, Wadsworth SC and Smith AE: Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 3: 117-127, 1996.
14. Dai Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnick N and Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92: 1401-1405, 1995.
15. Engelhardt JF, Ye X, Doranz B and Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91: 6196-6200, 1994.
16. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E and Wilson JM: Cellular immunity to viral antigens limits E l-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411, 1994.
17. Dong J-Y, Wang D, Van Ginkel FW, Pascual DW and Frizell RA: Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 7: 319-331, 1996.
18. Graham FL, Smiley J, Russell WC and Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-72, 1977.
19. Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, Aoyagi M, Hirakawa K and Hamada H: Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res 54: 5757-5760, 1994.
20. Niwa H, Yamamura K and Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-200, 1991.
21. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C and Saito I: Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 93: 1320-1324, 1996.
22. Graham FL and Prevec L: Manipulation of adenovirus vectors. In: Methods in molecular biology (Murray EJ, ed). Clifton, New Jersey, The Humana Press, 1991, pp 109-128.
23. Suga S, Yoshikawa T, Asano Y, Yazaki T and Ozaki T: Neutralizing antibody assay for human herpesvirus-6. J Med Virol 30: 14-19, 1990.
24. Kuriyama S, Yoshikawa M, Ishizaka S, Tsujii T, Ikenaka K, Kagawa T, Morita N and Mikoshiba K: A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Funct 16: 503-510, 1991.
25. MacGregor GR, Nolan GP, Fiering S, Roederer M and Herzenberg LA: Use of E. coli lac Z (ß-galactosidase) as a reporter gene. In: Methods in molecular biology (Murray EJ, ed.). Clifton, New Jersey, The Humana Press, 1991, pp 217-235.
26. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD and Wilson JM: In vivo correction of low density lipoprotein receptor deficiency in the Watanabe Heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 269: 13695-13702, 1994.
27. YangY, Trinchieri G and Wilson JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1: 890-893, 1995.
28. Rowe WP, Hartley JW and Huebner RJ: Serotype composition of the adenovirus group. Proc Soc Exp Biol Med 97: 465-470, 1958.
29. Weinberg A, Fink MC, Takimoto S, Ishida MA and Souza MC: Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population. Rev Inst Med Trop Sao Paulo 31: 336-340, 1989.
30. Rosenecker J, Harms KH, Bertele RM, Pohl Koppe A, v Mutins E, Adam D and Nicolai T: Adenovirus infection in cystic fibrosis patients: implication for the use of adenoviral vectors for gene transfer. Infection 24: 5-8, 1996.
31. Vilquin J-T, Guerette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R and Tremblay JP: FK506 immunosuppression to control the immune reactions triggered by first generation adenovirus-mediated gene transfer. Hum Gene Ther 6: 1391-1401, 1995.
32. Jooss K, Yang Y and Wilson JM: Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 7: 1555-1566, 1996.
33. Smith TAG, White BD, Gardner JM, Kaleko M and McClelland A: Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 3: 496-502, 1996.
34. Ilan Y, Jona VK, Sengupta K, Davidson A, Horwitz MS, RoyChowdhury N and Roy-Chowdhury J: Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 26: 949-956, 1997.
35. Lei D, Lehmann M, Shellito JE, Nelson S, Siegling A, Volk H-D and Kolls JK: Nondepleting anti-CD4 antibody treatment prolongs lung-directed El-deleted adenovirus-mediated gene expression in rats. Hum Gene Ther 7: 2273-2279 1996.
36. Scaria A, St George JA, Gregory RJ, Noelle RJ, Wadsworth SC, Smith AE and Kaplan JM: Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 4: 611-617, 1997.
37. YangY, Su Q, Grewal IS, Schilz R, Flavell RA and Wilson JM: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lungtissues. J Virol 70: 6370-6377, 1996.
38. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A, Ochs HD and Wilson CB: Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 94: 4686-4691, 1997.
39. Weiss A: T lymphocyte activation. In: Fundamental Immunology (Paul WE, ed). New York, Raven Press Ltd, 1993, pp 467-504.
40. Wang Q, Greenburg G, Bunch D, Farson D and Finer MH: Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther 4: 393-400, 1997.